XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) x. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxx stávajících xxxxxxxx xxxxx obsažených x xxxxxxxxxx xxxxxxxxxxx, které xxxx xxxxxxx x xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) č. 528/2012
(Text x významem xxx XXX)
XXXXXXXX KOMISE,
x xxxxxxx xx Xxxxxxx o fungování Xxxxxxxx xxxx,
x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. xxxxxx 2012 x dodávání xxxxxxxxxx xxxxxxxxx na xxx x xxxxxx xxxxxxxxx (1), x zejména xx čl. 89 xxxx. 1 xxxxx xxxxxxxxxxx xxxxxxxxx nařízení,
vzhledem x xxxxx důvodům:
(1) |
Xxxxxxxx Xxxxxx (ES) x. 1451/2007 (2) xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxx přezkumu xxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx (xxxx jen „xxxxxxx xxxxxxxx“), který xxx zahájen v souladu x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx byla zrušena x xxxxxxxxx xxxxxxxxx (XX) x. 528/2012, xxxx xx xxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx přizpůsobena ustanovením xxxxxxxxx xxxxxxxx. |
(2) |
Je xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx a typu xxxxxxxxx, xxxxx xxxxx xxx xxxxxxxx na trh x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx 89 xxxxxxxx (XX) x. 528/2012 s výhradou xxxxxxxxxxxxxx xxxxxxxx. Mělo xx xxxx xxx x x xxxxxxx xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx, xxxxx jsou hodnoceny x xxxxxxxx přezkumu. |
(3) |
Xxxxx xxxxxxxxx xxxxxxxx odchylky xxx xxxxxxxxx x xxxxxx xxxxx článku 6 xxxxxxxx (ES) x. 1451/2007, xxx xxxxxxxxxx se xx xxx xxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, xxxx xx xxx xxxxxx látky, xxxxx xxxxxxxx, hodnoceny x xxxxxxxx přezkumu pro xxxxxxxxx xxx přípravku. X xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx být xxxxxx dodávání xx xxx x xxxxxxxxx xxxxxxxx xx xx xxxxxxxx xxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx prohlášení xx xxx xxxxxxx, xxxxx přípravky tohoto xxxxxxxxxx využijí. Xxxxx xx xxxx platit x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx xxxxxxxxx x nové xxxxxxxx xxxx xxxxxxxxx v nařízení (XX) x. 528/2012 xxxxxx xxxxxxxx uvedené xx xxxxxxxx 98/8/ES xxxx xx řádně xxxxxxxxxx xxxxxxxxxxx Komise přijatým x xxxxxxx x xx. 3 xxxx. 3 xxxxxxxx (XX) x. 528/2012, xxxxxxxxxxx (xxxxxxxxx xxxxxxxxxxx xx věci X-420/10 (4)) xxxx xxxxxxxxx xxxxxx Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xxxxx se xxxxxxxx xxxxxxx. |
(4) |
Xxxxx biocidní přípravek xxxxxxxx xxxxxxx látku, xxxxx již xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, x této xxxxx xxxxxxx xxxx xx x xx xxxxxx, xxxxx současně xx používání xxxxxx xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxx nezbytné, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x dodávání xx xxx xxxxxxxx xx jeho xxxxxxxxxxxx, xx xxxxxxxx xxxxxxxx x xx xxxxxxxx xxxx. |
(5) |
X xxxxx xxxxxxxxxxx x xxxxxxxxxxxx by xxx xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx v programu xxxxxxxx ve všech xxxxxxxxxx částech totožný x xxxxxxxx xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx prováděcího xxxxxxxx Xxxxxx (XX) x. 88/2014 (5). |
(6) |
Pro xxxxx, xxxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx pro xxxxxxx, xx xxx xxxxxxxxx xxxxxxxxx xxxxx předložit xxxxxxxx xxxxx harmonizované xxxxxxxxxxx a označení xxxxx xxxxx čl. 37 odst. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) č. 1272/2008 (6), xxxxx jde x xxxxxxxxx vlastnosti xxxxxxxxxx xxxxx, x xxxxxxx by xxxx xxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxx xx xxxxxx xxxx xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx také xxxxxxxxxxx xxxxxxxx v xxxxxxx xxxxx, které xx xxxxxxxxx xxxxxxxx xxx xxxxx perzistentní, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, xxxxx xx xxxxx xxx považovány xx látky s vlastnostmi xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
(7) |
Xxx bylo xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx xx xxxxxxxx xxxx xxxxxxxxx x xx. 89 xxxx. 1 nařízení (XX) č. 528/2012, xxxx xx se xxxxxxxxx xxxxxx na xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, x xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx ve lhůtách xxxxxxxxxxx x xxxxxxxx (XX) x. 1451/2007 xxxx x xxxxx xxxxxxxx. Xxxxx xxxx by xx měly stanovit xxxxxx xxxxx xxx xxxxxxxxx xxxxxxxxx, xxxxxxx xx xx xxxx xxxx x xxxxx xxxxxxx, xx xxxxxxx xx xxxxx xxx xxxxxxxxx xxxx než xxx xxxx xxxxxxxxx xxxxxx xxxx. |
(8) |
Xxxxxxx xxxxxxxx xx přílohy I xxxxxxxxx 7 xxxxxxxx (XX) x. 528/2012 dosud xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xx xxxxx. Xx proto xxxxxx x této fázi xxxxxx xxxxxxx x xxxxxxxx xx xxxxxxx xxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6. |
(9) |
Xxx xxxxxx na čl. 90 xxxx. 2 xxxxxxxx (XX) č. 528/2012 xxxxxxx z článku 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx xxxxxxx v článku 10 xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx následné povolování xxxxxxxxxx xxxxxxxxx ve všech xxxxxxxxx. Xx xxxxx xxxxxx xxxxx xxxxx xxxxxxxxx tato xxxxxxxx xx xxxxx hodnoceních xxxxxxxx xxxxx. |
(10) |
Xxxxxxxxxxx xxxxxxxx programu xxxxxxxx xx xxx xxx možnost xx xx xxxxxxxx xxxxxx xxxxxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxx xxx xxxxxxxx za xxxxxxxxxxx, xx kvůli xxxx xxxxxxx ke zpoždění xxxxxxxxx z důvodu omezeného xxxxxxxx x xxxxxx, xxxxxxx jinak xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx znovu. |
(11) |
Xxxxxxx xx xxxxx x xxxxxxxx xxxxxxxx xxxxxxxxxx, xxxx xx být xxxxxxxxxx xxxxxxxx xx xx xxxxxxxxx. Xxxxx x xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxxxx, xxxxxx-xx této xxxxxxxx xxxxxxx xxx xxxxxx, xxxxx xxx xxxxxxx ke zpoždění xxxxxxxx xxxxxxxx, x xxxxxxxx-xx agentura již xxxxxxxx xx xxxx xxxxxxxxxx. |
(12) |
Xxxxx xx xxx xxxxxxxxx xxxxxx xxxxx xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxx identitě xxxxxxxx xxxxxxxxx látky, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx oficiálně zařazené xxxxx, xxxx by xxx xxxxx xxxx xxxxx v průběhu xxxxxxxxx xxxxx xxxxxxxxx a povolit xxxxx xxxxxx, xxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx. |
(13) |
Některé xxxxx zařazené do xxxxxxxx xxxxxxxx xxxxxx x xxxx xxxxxxx xxxxxx xxxxxxxx podporovány xxxxxx účastníkem. Xxxxx xx týká xxxxxxxx xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 xxxx. 4 xxxxxxxx (XX) č. 528/2012 tyto xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxx xxxx xxxxxxxx stanoveno. X xxxxxxxxx xxxxx a xxxxxxxxxxxxx xx xxxx xxx xxxxx možnost xxxxxxx xxxxx, protože xxxxx xx xxxx xxxxx x xxxxxxxxxxxxx xxxxxx xxx x xxxxxxxx xxxxxxxx vyloučeny. |
(14) |
Xxx xxxx xxxxxxxxx, xx žádná xxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxx xx něj xxxxxx xxxxxxxx, xxxx xx xxxxxxxx byla vyhodnocena, xxxx xx setrvání xxxxx, která ještě xxxxxx hodnocena, x xxxxxxxx xxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx x xx, |
XXXXXXX XXXX XXXXXXXX:
KAPITOLA 1
XXXXXXX X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx nařízení xxxxxxx xxxxxxxx pro xxxxxxxxx pracovního xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx účinných látek xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 xxxxxxxx (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Pro účely xxxxxx xxxxxxxx xx xxxxxxx xxxx xxxxxxxx:
x) |
„rozhodnutím x xxxxxxxxxxx“ xx xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxx xx. 9 xxxx. 1 písm. b) xxxxxxxx (XX) č. 528/2012 nebo xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx kombinaci nezařadit xx xxxxxxx I nebo IA xxxxxxxx 98/8/ES; |
x) |
„xxxxxxxxx látky x xxxx přípravku zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx II, xxxxx xxxxxxx xxxx podmínky:
|
x) |
„účastníkem“ xx xxxxxx osoba, xxxxx xxxxxxxxxx xxxxxx o xxxxxxxxx xxxxx x xxxx xxxxxxxxx zařazené do programu xxxxxxxx xxxx xxxxxxxxxx xxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxx podle xx. 17 xxxx. 5 xxxxxx nařízení, xxxx xxxxxx jménem xxxx xxxx xxxxxx xxxx xxxxxxxx xxxxxxxxxx; |
x) |
„hodnotícím xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx uvedeného x xxxxxxx XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) č. 528/2012. |
KAPITOLA 2
POSTUP XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxx X xxxxxxxx (EU) č. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx o schválení xx xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012 může xxxxx xxxxx účastník, x xxxxx xxxxxxxx xxxxx xxxxxxxx k xxxxxx, že xxxxxxxx xxxxxxxxxx xxxxx čl. 17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx žádost xxxx xxxxxxxx xx&xxxx;xxxxxxx I nařízení (XX) č. 528/2012, může xx xxxxx xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené x&xxxx;xxxxxxxx 1 se xxxxxxxx xxxxxxxx xx&xxxx;xxxx let xx prohlášení o souladu x požadavky podle xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Xxxxxxx xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx o xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx nařízení Xxxxxx (XX) č. 564/2013 (7) x xxxxxxx žádost, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx ve xxxxx 30 xxx. X xxxx xxxxxxxxxxx informuje xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx.
2. Po xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx nařízení (XX) x. 564/2013 přijme xxxxxxxx xxxxxx x xxxxxxxxx x tom účastníka x xxxxxxxxx příslušný xxxxx, xxxxxxx uvede xxxxx xxxxxxx xxxxxxx x xxxx xxxxxxxxx xxxxxxxxxxxxx kód.
3. Xxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 1 tohoto xxxxxx xxx xxxxx xxxxxxx prostředek x xxxxxxx s xxxxxxx 77 xxxxxxxx (EU) x. 528/2012.
4. Xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx splatném xxxxx čl. 80 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xx 30 xxx xxxx, xx agentura xxxxxxx xxxxxx, x xxxxxxx xxxxxx, pokud xxxxxxxx xxxxxxxxx poplatek xx xxxxx 30 xxx. X xxxx xxxxxxxxxxx informuje xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012
1. Xxxxx xxxxxxxx přijme xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx obsahuje xxxxx xxxxxxxxxx x xxxxxxx s čl. 6 xxxx. 1 x 2 xxxxxxxxx xxxxxxxx, x xxx xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxx do 30 xxx xx xxxxxxxxx xxxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx od účastníka xxxxxxxxxxx xxxxx xxxxxxxx (XX) x. 1451/2007, xxxxx ta xxxxx nebyla uznána xxxx xxxxx xxxxx xxxxxx 13 uvedeného xxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. ledna 2015.
3. X xxxxxxxxx uvedených x xxxxxxxxxx 1 x 2 hodnotící xxxxxxxxx xxxxx neprovádí xxxxxxxxx kvality xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxx.
4. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx xxxxxx je xxxxxxx, xxxxx xxxxxxxxxxx, xxxx doplňující xxxxxxxxx xxxx k xxxxxxxxx xxxxxxx nutné, a x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Tato xxxxx xxxxx xxxxxxxxxx 90 dnů.
Xxxxxxxx-xx xxxxxxxxx příslušný orgán, xx předložené xxxxxxxxxx xxxxxxxxx postačují ke xxxxxxx xxxxxxxxx xxxxxxxxx x odstavci 2, xxxxxxx xxxxxx xx 30 dnů od xxxxxxxx xxxxxxxxxxxx informací.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, hodnotící xxxxxxxxx xxxxx xxxxxx xxxxxxx x informuje x xxxx skutečnosti xxxxxxxxx x xxxxxxxx. V xxxxxx případech xx xxxxx xxxxxxxx zaplacené x xxxxxxx s čl. 80 xxxx. 1 x 2 xxxxxxxx (EU) x. 528/2012.
Xxx potvrzení xxxxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx a další xxxxxxxxx xxxxxx x xxxxx xxxxx xxxxxx potvrzení.
Xxxxxx 6
Hodnocení xxxxxxx
1. Xxxxx xxxxxx se použije, xxxxx platí xxxxxxx x xxxxxx xxxxxxxx:
a) |
xx-xx xxxxxx xxxxxxxxx xxxxx xxxxxx 5; |
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxxxx xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, xxx xxxxx xxxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 14 odst. 4 uvedeného xxxxxxxx; |
x) |
xxxxx agentura přijala xxxxxx x zařazení xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 podle xx. 4 xxxx. 2 a xxx xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4. |
2. Xxxxxxxxx xxxxxxxxx xxxxx zhodnotí xxxxxx xxxxx článků 4 a 5 xxxxxxxx (XX) č. 528/2012 x xxxxxxxx xxx xxxxxxx xxxxxx xx xxxxxx xxxxxxxxx xx xxxxx xxxxxxxxxx x xxxxxxx s xx. 6 xxxx. 3 xxxxxxxxx nařízení x zašle xxxxxxxxx xxxxxx a závěry xxxxx hodnocení xxxxxxxx.
3. Xxxxx xxxxxxx kombinaci xxxxx x typu přípravků xxxxxxxxx několik účastníků, xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx x xxxxxx xxxxx x xxxxx x xxxxxx xxxx, xxxxx xxxx, xx xxxxxxx xxxxxxx:
x) |
365 xxx po xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x) xxxx zaplacení xxxxxxxx xxxxxxxxx v odst. 1 písm. c) x xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx; |
x) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
4. Xxxx tím, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxx své xxxxxx xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx xx 30 xxx x xxxxxxxxx xxxxxx x x xxxxxxx hodnocení xxxxxxx xxxxxxxxxx. Hodnotící xxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx xxxx xxxxx xxxxxxxxx.
5. Xxxxx xx xxxxx, xx xxxx x xxxxxxxxx nutné xxxxxxxxxx informace, hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xx stanovené xxxxx předložil, x xxxxxxxxx x tom xxxxxxxx.
Xxxxx 365 xxx xxxxxxx x xxxxxxxx 3 se xxxxxxx xx xxxx ode xxx vznesení požadavku xx dne xxxxxxxx xxxxxxxxx. Xxxxx xx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx okolnostmi, xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx lhůty:
x) |
365 xxx x xxxxxxx, xx xx xxxxxxxxxx informace xxxxxx xxxxxx, které xxxxxx xxxxxx x xxxxx směrnice 98/8/ES xxxx x xxxxx xxxxxxx xxxxxxxxxxx pro xxxxxxxxxxx xxxxxxx směrnice; |
x) |
180 xxx xx xxxxx ostatních xxxxxxxxx. |
6. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx existují xxxxx xxxxxxx xxxxxx xxxx xxxx zvířat xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx xxxxxx xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxx oddílu XX xxxx 3 xxxxxxx XX nařízení Evropského xxxxxxxxxx x Rady (XX) x. 1907/2006 (8) x xxxxxx xx xx svých xxxxxx.
7. X xxxxxxx xxxxxxx xx dokončení hodnocení xxxxxxxxxxxxx xxxxxxxxx příslušný xxxxx xxx xxxxxxxxxx xxxxxxx a nejpozději při xxxxxxxxxx xxxxxxxxx zprávy xxxxx odstavce 3:
x) |
předloží xxxxx xxxxxxxx xxxxx xx. 37 odst. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx xxxxxxx, že je xxxxxxx jedno z kritérií xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx xxxxxxxx, xxx xxxx xxxxxxxx xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
b) |
konzultuje x xxxxxxxxx, xxxxx xx xxxxxxx, xx xxxxx x xxxxxxxx čl. 5 xxxx. 1 xxxx. x) xxxx x) nařízení (XX) x. 528/2012 nebo xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx xxxxxxxx xxxx xxxxxxx, ale xxxxxx xxxxxxxx xxxxxx x xxxxxxx XXX xxxxxxxx (ES) x. 1907/2006 xxxx x xxxxxxx xxxxxxxx x xx. 59 odst. 1 xxxxxxxxx nařízení. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
x) |
pokud hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx zprávu podle xx. 6 odst. 2 x xxxxxxxx předložil návrh xxxx xxxxxxx konzultaci xxxxx xx. 6 odst. 7; |
x) |
xxxxx xxxx xxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 14 odst. 4 xxxxxxxx (XX) x. 1451/2007, xxx hodnotící xxxxxx xxxxx xxxxxxxxxxxx Xxxxx xxxxx pro xxxxxxxx xxxxxxxxx podle xx. 15 xxxx. 4 xxxxxxxxx xxxxxxxx. |
2. Xx xxxxxxx zprávy xxxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx o schválení kombinace xxxxx a typu xxxxxxxxx xxxx jeho xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, s ohledem xx xxxxxx xxxxxxxxxxx příslušného xxxxxx.
Xxxxxxxx zahájí xxxxxxxx xxxxxxxxxx v jedné x xxxxxx xxxx, xxxxx toho, xx xxxxxxx později:
a) |
do xxx xxxxxx po xxxxxxx xxxxxx; |
b) |
xx xxxxx xxxxxxxxx v příloze III. |
Xxxxxxxx xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx xx xxxx xxxxxxxx
1. Xxx přípravě xxxxx xxxxxxxxxx xxxxx čl. 7 xxxx. 2 agentura xxxxxxx, xxx účinná látka xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx v čl. 10 odst. 1 xxxxxxxx (EU) x. 528/2012, x xxxx xxxxxx zmíní xx xxxx stanovisku.
2. Xxxx jsou xxxxxxx xxxxxx 66 x 67 xxxxxxxx (XX) x. 528/2012, dříve než xxxxxxxx xxxxxxxx xxx xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx se xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; x xxxx době xxxxx xxxxxxxxxx třetí strany xxxxxxxxx příslušné xxxxxxxxx xxxxxx informací o dostupných xxxxxxxxx. Agentura xxxxxxxx xxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxxxx.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx x xxxxxxx jedno x xxxxxxxx xxxxxxxxxxx x xx. 10 xxxx. 1 nařízení (XX) x. 528/2012, xxxx xxx xxxxxxxx za látku, xxxxx se xx xxxxxxxx, x xxxxxxxx xxxxxxxx x xxxxxxx x xx. 89 odst. 1 xxxxxx pododstavcem xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Rozhodnutí Komise
Xx xxxxxxxx stanoviska xxxxxxxx xxxxx xx. 7 xxxx. 2 Xxxxxx xxx zbytečného xxxxxxxx připraví xxxxx xxxxxxxxxx xxx přijetí xxxxx xx. 89 odst. 1, xxxx případně xxxxx xx. 28 xxxx. 1 nařízení (XX) č. 528/2012.
XXXXXXXX 3
XXXXX XXXXX XXXXXXXX XXXXXXXX
Xxxxxx 10
Xxxxxxxxx xxxx nahrazení xxxxxxxxx xx xxxxxxxx dohodě
1. Roli xxxxxxxxx xx možno xx xxxxxxxx dohodě xxxx xxxxxxxxxx účastníkem x potenciálním xxxxxxxxxx xxxxxxx xxxx sdílet xx předpokladu, xx xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx se xx xxxxxxx xxxxx xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx pro xxxxx tohoto xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx a stávající xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (xxxx xxx „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx všechna příslušná xxxxxxxx x xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx oznámení splňujícího xxxxxxxxx podle odstavce 2 xxxxxxxx xxxxxxxxxxx xxxxxxxxx v rejstříku týkající xx totožnosti účastníka.
4. Osoba xxxxxxx na území Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx nebo xx xxxxxxxxx k xxxxxxxxxxx xxxxx xxxxxx xxxxxx, xx xxx xxxxx xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 považována xx xxxxx, xxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení xxxxxxxxx
1. Xx xx xx xx, xx účastník xxxxxxxxx x xxxxxx xx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx, v xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxxxx xxxxxxxx xxxx hodnotící příslušný xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx záměru xxxxxxxxx; |
x) |
xxxxx nepředložil xxxxxx xx lhůtě xxxxxxx x xx. 3 xxxx. 2; |
x) |
xxxxx jeho xxxxxx byla xxxxxxxxx xxxxx xx. 4 odst. 1, xx. 4 odst. 4 xxxx xx. 5 xxxx. 4; |
x) |
xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxx uvedených x xx. 6 xxxx. 5; |
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx nebo xxxxxxxx. |
2. Odstoupení xx považuje xx xxxxxxxxx xxxx, xxxxx x xxxx xxxxxxx xx xxxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx zprávu xxxxxxxxxxx xxxxxx podle xx. 6 xxxx. 4 tohoto xxxxxxxx.
Xxxxxx 12
Xxxxxxxx včasného xxxxxxxxxx
1. Xxxxx je x xxxxxxx xxxxxxxxxx informován xxxxxxxxx xxxxxxxxx orgán, xxx xxxxxx agentura, xxxxxxxxx xx hodnotící xxxxxxxxx xxxxx xxx xxxxxxxxxx odkladu prostřednictvím xxxxxxxxx.
2. Xxxxx xx o xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, aktualizuje xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx přezkumu xxxx xxxxxxxxxx xxxxxxx účastníci xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx xxxx xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx dříve xxxxxxxx, xxxxxxxxx o tom xxxxxxxx xxxxxxxxxxxxxxx rejstříku Xxxxxx.
Xxxxxx 13
Nová xxxxxxxx xxxxxxxxx xxxxx
1. Pokud xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx závěry xxxxxxxx xx xxxxx, xxx jsou uvedeny x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxx xxxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Hodnotící xxxxxxxxx xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx se xxxxxxxx látky.
Xxxxxx 14
Převzetí role xxxxxxxxx
1. Xxxxxxxx zveřejní otevřenou xxxxx x xxxxxxxx xxxx xxxxxxxxx xxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, pokud xxxxxxx xxxxx z těchto xxxxxxx:
x) |
xxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx přípravku včas xxxxxxxxxx podle xxxxxx 11 x xxxxxx xxxx xxxxxxxxx xxx danou kombinaci xxxxxx xxxxxxx xxxxxxxx; |
x) |
xx xxxxxxx xxxx xxxxxxxx xxxxx xxxxxx 13; v tomto případě xx xxxxx xxxx xxxxx xx látky, xx xxxxxx se xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx nikoliv nová xxxxxxxx látky. |
2. Xx xxxxxxxx xxxxxx xxx dne zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx oznámení pro xxxxxxxxx xxxxx xxxxxx 17.
3. Xx xxxxxxxx měsíců xx xxxx xxxxxx xxxxxx nařízení x xxxxxxxx xxxx kterákoli xxxxx oznámit xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx xx xxxxx 2 xxxxxxx XX podle xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx pro xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xx xxxxxx xx xxx, xxxxxxx ze stávající xxxxxx xxxxx, xxx xxxx xxxxxxxxx ani xxxxxxxx xx programu xxxxxxxx pro tento xxx xxxxxxxxx x xxxx xxxxxxxx do xxxxxxx I xxxxxxxxx xxxxxxxx, xxxx xxxxx xxxxxxxx xxxx se x xx xxxxxx, xx uvedená xxxxx xxxxxxxxx pro xxxxxxxx xx xxxxxxxx xxxxxxxx pro xxxxxxxxx xxx přípravku xx xxxxxxx xxxxxxxxx x xxxxxx xxxxxx:
x) |
xxxxx uvádějící xxxxxxx xx xxx se spoléhala xx xxxxxx nebo xxxxxxx xxxxxxxxxx vydané Xxxxxx nebo xxxxxxxxxx xxxxxxx jmenovaným v souladu x xxxxxxx 26 směrnice 98/8/XX nebo xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, xxxxx xx základě xxxxxxxxxx opodstatněných xxxxxx xxxxx uvedené xxxxxx xx xxxxxxxxxx x xxxxxxxxxxx, xx xxxxxxx byl xxxxx x xxxxxxxxxx xxxxxxxx 98/8/XX nebo xxxxxxxx (XX) x. 528/2012, nebo xx byl příslušný xxx xxxxxxxxx jedním x xxxxxxxxx, xxx xxxxx xxxx xxxxxx xxxxx xxxxxxxx, a xxxxx xxxx xxxxxxx xxxxxx xx doporučení xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxxx podle xx. 3 xxxx. 3 xxxxxxxx (XX) x. 528/2012 xxxx v nových, xxxxxxxxx xxxxxxxx zveřejněných Komisí; |
b) |
xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
c) |
xxxxxxxx xxxxxxxxx xxxxx podle xxxxxxxx (XX) x. 528/2012 x xxxxxxxxx typu xxxxxxxxx, xxx xxxx bylo xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx xxxxxxxxxx těchto xxxx xxxxxxxxx x xxxxxxxx xxxxx zařazenou xx xxxxxxxx xxxxxxxx pro původní xxx xxxxxxxxx, ale xxxxxx pro nový. |
Xxxxxx 16
Xxxxxxxxxx o xxxxx xx xxxxxxxx
1. Prohlášení x xxxxx oznámit látku, xxxxx xx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx podle xxxxxx 15, xxxxxxxxx prostřednictvím xxxxxxxxx kterákoli xxxxx, xxx má zájem xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxxxxxx x xxxxxxxxxxxxx příjemců:
x) |
Xxxxxx xxxxxxxxxx dvanáct xxxxxx xx xxxxxxxxxx xxxxxxxxxx xxxx pokynů xxxxxxxxx x xx. 15 xxxx. x); |
x) |
xxxxxxxx xxxxxxxxxx 30. října 2015 x xxxxxxxxx xxxxxxxxx x čl. 15 písm. b); |
x) |
Komisi xxxxxxxxxx 30. xxxxx 2015 x případech xxxxxxxxx x xx. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx obsahovat xxxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx v čl. 15 xxxx. x) xxxx prohlášení xxxxxxxxx xxxxxxxxxxxx odůvodnění, x xxxx xxxxxxx, xx xxxx splněny xxxxxxx podmínky x xxx uvedené.
3. Xxxxx xxxx xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x) nebo x) x Xxxxxx xxxxxxx po xxxxxxxxxx s členskými xxxxx x xxxxxx, xx xxxxxxxx 6 není xxxxxxxxxx, x xxxxxxxx, že xxxx splněny xxxxxxxx xxx xxxxxxxx uvedené x xx. 15 písm. x), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx xxxx xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. b) xxxx xxxxx Xxxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxx s uvedením xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Xxx účely xxxxxx xxxxxxxx xx xxxxxxxxxx xxxxx xx. 3x xxxx. 3 xxxxxxx pododstavce xxxxxxxx (XX) č. 1451/2007 xxxxxxxx xx xxxxxxxxxx xxxxx tohoto xxxxxxxx.
5. Kterákoli xxxxx, která xx xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxx může xxxxxx podle xxxxxx 17 do šesti měsíců xxx xxx xxxxxxxxxx xxxxx odstavce 4.
6. X xxxxxxxxx xxxxxxxxx x čl. 15 písm. x) x x) se xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxx za xxxxxxxxx účastníkem x xxxx xxxxxxxxx x xxxxxxx xxxxxxxx, xxxxx jsou xxxxxxx xxxx xxxxxxxx:
x) |
příslušná xxxxxx látka xx xxx xxxxxxxx do programu xxxxxxxx; |
x) |
xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx účinnou látku xxx xxxxxxxx xxxxxxx xxxxx, které xxxx xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx; |
x) |
účastník, který xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, xx xx xxxxx x xxxxxxx xxxx xxxxxxxxx látky x xxxx přípravku. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Oznámení xxxxx xx. 14 xxxx. 2 x 3 xxxx xx. 16 xxxx. 5 se xxxxxxxxxxx agentuře prostřednictvím xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx formátu XXXXXX. Musí xxxxxxxxx xxxxx xxxxxxx v xxxxxxx X.
3. Pokud xxxx x xxxxxxx XX xxx xxxxxxxx xxxxxxx látku uveden xxxxxxxxx příslušný orgán, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx xxx vybraného xxxxxxxxxxx xxxxxx, xxxxx xx jmenován v souladu x xxxxxxx 81 nařízení (XX) x. 528/2012, a poskytne písemné xxxxxxxxx dokládající, xx xxxxxxxxx xxxxx xxxxxxxx s xxx, xx dokumentaci xxxxxxx.
4. Xx obdržení oznámení x tom xxxxxxx xxxxxxxx Xxxxxx a xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xx 30 dnů xx přijetí uvedené xxxxxxxxx, agentura xxxxxxxx xxxxxxx a xxxxxxx x tom oznamovatele x Xxxxxx.
5. Xx xxxxxxxx xxxxxxxx agentura xx 30 dnů xxxxx, xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx, xxxxxxxx agentura xxxxxxxxxxxx lhůtu x xxxxx 30 xxx, xxx své xxxxxxxx xxxxxxx xxxx xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx xxxxx xxxxxxxx xx 30 dnů xxx prohlásí, xx xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, xxxx xxxxxxxx xxxxxxx, x xxx xxxxxxxxxx sdělí xxxxxxxxxxxx x Komisi.
6. X xxxxxxx x xxxxxxx 77 nařízení (EU) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 xxxx 5 xxxxx opravný xxxxxxxxxx.
7. Xxxxx oznámení xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
x) |
v xxxxxxx, že xxxx xxxxxxxx předloženo podle xx. 14 odst. 2 xxxx 3, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx se xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx; |
x) |
x xxxxxxx, xx xxxxxxxx bylo xxxxxxxxxx xxxxx xx. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Komisi, xx xxxxxxxxxx xxxx vyhověno. |
Xxxxxx 18
Xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx považována xx xxxxxxxxx v souladu x xx. 16 xxxx. 6 xxxx xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x dodržení xxxxxxxxx x souladu x xx. 17 xxxx. 7 xxxx. x), zařadí Xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Informace x xxxxxxx, xxxxx nejsou xxxxxx podporovány x xxxxx programu xxxxxxxx
Pokud xxxxxx xx xxxxx stanovené x xx. 16 xxxx. 5 xxxxxxxx xxxxx oznámení xxxx xxxxx xxxx xxxxxxxx xxxxxxx xx zmíněném xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx agenturou podle xx. 17 xxxx. 4 xxxx 5, xxxxxxxx x xxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxxx rejstříku a zveřejní xxxx informaci xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Xxxxxx x látkách, xxxxx xxxxxx nadále xxxxxxxxxxx x xxxxx programu xxxxxxxx
Xxxxxx xxxxxxxx návrh xxxxxxxxxx x xxxxxxxxxxx xxxxx čl. 89 odst. 1 xxxxxxx xxxxxxxxxxx nařízení (XX) x. 528/2012 v těchto xxxxxxxxx:
x) |
xxxxx agentura xxxxxxxxx Xxxxxx o včasném xxxxxxxxxx xxxxxxxxx podle xx. 12 xxxx. 3 xxxxxx nařízení; |
x) |
xxxxx xxxxx xxxxx xxxxxxxx xxxxxxxx ve lhůtách xxxxxxxxxxx x xx. 14 odst. 2 xxxx 3 xxxxxx xxxxxxxx xxxx pokud xxxx xxxxxxxx předloženo x xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5; |
c) |
pokud xxxx xxxxxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx v čl. 14 xxxx. 2 xxxx 3 tohoto xxxxxxxx a byly xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx nařízení, xxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx xxxx stávající identity x xxxxxxx XX tohoto nařízení. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. x) se xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, na kterou xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx nebo jakékoli xxxxxxxxxx x xxxxxxxxx.
XXXXXXXX 4
XXXXXXXXX XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx xxx xxxxx uvedené v článku 15
1. Členský xxxx může xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx na trh x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx xxxxx xxxxxxx x čl. 15 xxxx. b) x x), tuto xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx xxxxxxxxx:
x) |
xxxxx být xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx xxxxxx tohoto xxxxxxxx v platnost; |
b) |
stávající zásoby xxxxxxxxxx přípravku mohou xxx dále xxxxxxxxx xx&xxxx;30 měsíců xx xxx xxxxxx xxxxxx xxxxxxxx v platnost. |
2. Členský xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx systému xxxx praxe xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx účinné xxxxx uvedené v xx. 15 písm. x), tuto xxxxx xxxxxxxx xxxx x xx vzniká. V xxxxxx případech:
a) |
nesmí xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 měsíců xx xx x dále xxxxxxxxx událostí, která xxxxxxx později:
|
b) |
stávající xxxxxx biocidního xxxxxxxxx xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 xxxxxx xx xx z xxxx uvedených událostí, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx stát může xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx účinné xxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 odst. 4 xxx příslušný xxx výrobku, xxxx xxxxx obsahuje nebo x ní xxxxxx. X xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx přípravek xxxxxx dodáván na trh x&xxxx;xxxxxxx od dvanácti měsíců xx xxxx, xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx podle článku 19 x |
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx uvedeného xxxxxxxxxx. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx xx. 55 xxxx. 1 xxxxxxxx (XX) x. 528/2012, do osmnácti měsíců xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxx, xxxxx členský xxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx uvedených x xx. 5 xxxx. 2 xxxxxx pododstavci xxxx. x) nebo x) nařízení (EU) x. 528/2012, tento členský xxxx může xxxxxxxxx Xxxxxx xxxxxxxxxxx xxxxxx x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx stát xxxxxxxx odůvodněnou žádost xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxxxx xxxxxxxx xxxxxxx informace, žádající xxxxxxx xxxx musí xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx zveřejní žádost xxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx xxxxx xxxx xxxx xxxxx mohou xxxxx xxxxxxxxxx xx xxxxx 60 xxx po xxxxxxxxxx.
4. Xx xxxxxxx obdržených xxxxxxxxxx xxxx Xxxxxx xxxxxxx odchylku od čl. 89 xxxx. 2 druhého pododstavce xxxxxxxx (XX) x. 528/2012, xxxxx umožní uvádět xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx z xxxx xxxxx, obsahují xx xxxx z xx xxxxxxxx, na xxx xxxxxxxxxx členského xxxxx x xxxxxxxx xx v daném xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx xxxxxxxx předpisy x x xxxxxxxx podmínek xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx Xxxxxx.
5. Xxxxxxx xxxx, jemuž xx xxxxxxxx odchylka:
a) |
zajistí, xx xxxxx xxxxxxxxx xxxx xxxxxxx xx xxxxxx případy x xxxxxxx dobu, xxx xxxx xxxxxx podmínky xxxxxxxx 1; |
x) |
xxxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxx, aby xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxx, zvířat xxxx xxxxxxxxx xxxxxxxxx; |
x) |
xxxxxxx, xxx xx xxxxxxx alternativní xxxxxx nebo aby xxxx xxxx před xxxxxxxxx xxxxxxxxx odchylky xxxxxxxxxx xxxxxx o schválení xxxxxx xxxxx x xxxxxxx xxxxxxx 7 nařízení (XX) x. 528/2012. |
KAPITOLA 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx xx xxxxxxxx (XX) x. 1451/2007.
Odkazy xx xxxxxxx xxxxxxxx xx považují xx xxxxxx xx toto xxxxxxxx.
Xxxxxx 24
Xxxxx x xxxxxxxx
Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Úředním xxxxxxxx Xxxxxxxx unie.
Xxxx xxxxxxxx je xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx ve xxxxx xxxxxxxxx xxxxxxx.
X Bruselu xxx 4. srpna 2014.
Xx Komisi
xxxxxxxx
Xxxx Xxxxxx XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. X 167, 27.6.2012, x. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Xxxxxx (XX) x. 1451/2007 ze xxx 4. prosince 2007 x xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx v xx. 16 xxxx. 2 směrnice Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx přípravků xx xxx (Úř. věst. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Xxxx 98/8/ES xx xxx 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Úř. xxxx. L 123, 24.4.1998, s. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxx xxxxx (xxxxxxx xxxxxx) ze xxx 1. března 2012 (žádost x xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Hamburg – Xxxxxxx) – Xöxx GmbH xxxxx Xxxxx XxxX (uvádění xxxxxxxxxx xxxxxxxxx xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. x) – xxxxx „xxxxxxxx přípravky“ – xxxxxxxxx, který xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx xx xxxx, xxxxxxxx xxxx xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) x.&xxxx;88/2014 ze xxx 31. ledna 2014, xxxxxx xx stanoví xxxxxx xxx xxxxx xxxxxxx X&xxxx;xxxxxxxx Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx používání (Xx. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (ES) x. 1272/2008 xx xxx 16. prosince 2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x směsí, x xxxxx a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006 (Xx. věst. X&xxxx;353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx nařízení Komise (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx agentuře pro xxxxxxxx xxxxx xxxxx xxxxxxxx Evropského xxxxxxxxxx x&xxxx;Xxxx (EU) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh x&xxxx;xxxxxx xxxxxxxxx (Úř. věst. L 167, 19.6.2013, s. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 xx xxx 18. prosince 2006 x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx látek, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/XX a x xxxxxxx xxxxxxxx Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/EHS a xxxxxxx Komise 91/155/EHS, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX X
Xxxxxxxxx požadované xxx xxxxxxxx podle xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 obsahuje xxxx xxxxxxxxx:
1) |
xxxxx, xx xxxxx xx stávající xxxxxxx xxxxxx xx xxxxxx čl. 3 xxxx. 1 xxxx. x) xxxxxxxx (XX) č. 528/2012; |
2) |
údaje o xxxx/xxxxxx přípravku, xx xxxxx/x xx oznámení xxxxxxxx; |
3) |
xxxxxxxxx o všech xxxxxxxx, xxxxx xxxx xxxxxx xxx xxxxx xxxxxxx x xxxxxxxxx xx zařazení xx xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx dokončení; |
4) |
xxxxxxxxx xxxxxxx v oddílech
|
5) |
xxxxx xxxx toto xxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x), xxxxx, xx xxxxx byla xx xxxx jako xxxxxx xxxxx biocidního xxxxxxxxx xxxxxxxxxxx do příslušného xxxx xxxxxxxxx v den oznámení xxxx zveřejnění rozhodnutí xxxx xxxxxx xxxxxxxxx xx xxxxxxxx písmenu. |
XXXXXXX II
XXXXXXXXX LÁTKY X XXXX XXXXXXXXX ZAŘAZENÉ XX XXXXXXXX XXXXXXXX XXX 4. XXXXX 2014
XXXX 1
Xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx dni 4. xxxxx 2014, s výjimkou xxxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx těch, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxxxxxx 1017 x 1019.
Xxxxx xxxxxxx |
Xxxxx látky |
Členský stát xxxxxxxxx |
Xxxxx ES |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
6 |
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx mravenčí |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
DE |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
kyselina xxxxxxxxxx |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
DE |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
xxxxxxxx xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx kyselina/2-hydroxyethanová xxxxxxxx |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
kyselina xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (rotenon) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
85 |
xxxxxxxxx |
UK |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
ES |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
FI |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
154 |
xxxxxxxxx |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-xxxxxxxxxxx-1-xx |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
172 |
cetylpyridinium-chlorid/1-hexadecylpyridin-1-ium-chlorid |
UK |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
180 |
(natrium-kakodylát) – xxxxxxx-xxxxxxxxxxxxxxx |
PT |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (xxxxx sůl xxxxxxxxxxxxxxx – xxxxxxxxx X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
kalium-dimethyldithiokarbamát |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (thiabendazol) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
235 |
diuron |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
DE |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (xxxxxxx) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (dichlofluanid) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
289 |
xxxxxxxxxxxx xxxxx |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx vápno/hašené xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx vápno/nehašené xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
FR |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
315 |
butan-2-on-peroxid |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
monolinuron |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
SI |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
PL |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (reakční xxxxxxxx ethylenglykolu x xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, sodná xxx (xxxxxxxxx xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
PL |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (TMAD) |
XX |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
387 |
dimorfolinomethan (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
401 |
xxxxxxx |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
403 |
měď |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
439 |
peroxid xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
IT |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
458 |
síran amonný |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
473 |
xxxxxxxxxx x pyrethroidy |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
491 |
oxid chloričitý |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
515 |
xxxxxx xxxxxx |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
ES |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
531 |
(benzyloxy)methanol |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx komplex (xxxxxxxxx xxxx) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
541 |
natrium-4-chlor-3-methylfenolát |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
PT |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
UK |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
563 |
kalium-(E,E)-hexa-2,4-dienoát (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (XXX) |
UK |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
ES |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
XX |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
590 |
3-(4-isopropylfenyl)-1,1-dimethylmočovina/isoproturon |
DE |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxx) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
S-[(6-chlor-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl]-O,O-dimethyl-fosforothioát (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
961 |
oxid vápenato-hořečnatý/dolomitické xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (cyfenothrin) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
608 |
dimethyl(tetradecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
609 |
xxx- x xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
UK |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
618 |
[1-xxxxxxx-2-xxxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (empenthrin) |
BE |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx kokosového xxxxx (XXXXX/XXXX) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
N |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (DDAC) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
AT |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (MMPP) |
PL |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx indica, xxxxxxx |
DE |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (C12-C14)) |
IT |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
725 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxx (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, výtažek |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
744 |
xxxxxxxxx xxxxxx, Xxxxxxxxx xxxxxxx, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (hexaflumuron) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx x X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (xxxxxxxxxxxxx) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (BBIT) |
CZ |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
792 |
komplex xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
SE |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
794 |
sek-butyl-2,2-(2-hydroxyethyl)piperidin-1-karboxylát (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-xxxxxxxxxx (xxxx xxxxxxxxxxxxx) (xxxxxxxxxxx) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
952 |
Bacillus xxxxxxxxxx 2362, xxxx XXXX-1743 |
IT |
mikroorganismus |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. israelensis, xxxx XX3X |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
957 |
Xxxxxxxx xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) a 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), xxxx (3:1) (směs XXXX/XXX) |
XX |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
939 |
aktivní xxxxx (xxxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxx in xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx kyselina |
FR |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
xxxx relevantní |
není xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
není xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx sudým číslem), xxxxxxxx xxxxxx s xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx a xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
777 |
xxxxxxx xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx xxxxx xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx stabilního agregátu x xxxxxxxxxx xxxxxxxxx xx xxxxxxxxxx) |
SE |
xxxx x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (xxxx xxxxxxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
831 |
křemelina |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 izomerů 1R xxxxx, 1X: 1R xxxxx, 1X: 1R xxx, 1R: 1X xxx, 1S 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
835 |
xxxxxxxxxxxx/(X)-(3-xxxxxxxxxxx)xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx na ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (chlorfenapyr) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) x (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/polymerní xxxxxxxxx xxxxxxx xxxxxx (XX Polymer) |
XX |
xxxxxxx |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (PHMB) |
FR |
polymer |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
868 |
poly(biguanid-1,5-diylhexan-1,6-diyl-hydrochlorid) |
XX |
xxxxxxx |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
XX |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (polymerický xxxxxx) |
EL |
polymer |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
ČÁST 2
Xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxx 4. xxxxx 2014
Xxxx část xxxx xxxxxxx xxxxxxxx
— |
xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx níže, xxxxxx xxxxxxxxxx nanoforem, |
— |
jakékoli xxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, xxxxx xxxx xxxxxxx x xxxxxxx, x |
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx účinných látek x xxxx xxxxxxxxx schválených xx 4. xxxxx 2014, x xxxxxxxx xxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx. |
Kombinace xxxxx a typu xxxxxxxxx x xxxxxxxxxxxxx zařazené xx xxxx xxxxx xxxxx předmětem rozhodnutí x xxxxxxxxxxx xxxxx xxxxxx 20, xxxxxxxx xxxxx osoba xxxxxx xxxxxxxx xx xxxxxxxx xxxxxx xx vstupu xxxxxx xxxxxxxx v platnost xxxxx xx. 14 xxxx. 3 xxxx xxxxx xx xxxxxx xxxxxxxx zamítnuto podle xx. 17 odst. 4 xxxx 5.
Xxxxx xxxxxxx |
Xxxxx látky |
Členský xxxx xxxxxxxxx |
Číslo ES |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (nově xxxxxxxxxx xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx amorfní |
FR |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
449 |
síran xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
decyl(dimethyl)oktylamonium-chlorid (viz xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
IE |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
637 |
alkyl(benzyl)dimethylamonium-chloridy (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (viz položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx) (xxx xxxxxxx 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
dialkyl(C6-C12)dimethylamonium-chloridy (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
alkyl(C10-C16)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx jiný xxx z jader xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxxxxxxxx xxxxx x xxxx xxxxxxxxxx organickými xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx xxxxxxx 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx produkt dimethyl-adipátu, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
směs |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(dialkyl)dimethylamonium-chloridy, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) nasycené x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx kyselin loje, xxxxxxxxxx xxxxx a xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) xxxxxxxx x xxxxxxxxxx, odvozené xx xxxxxxxx kyselin xxxx, kokosového oleje x sójového xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x seznamu XXXXXX |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxxxxx) (xxxxxx (X8-X22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx od xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx a sójového oleje) (XXX) |
XX |
xxxx xxxxx uvedených x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
IE |
není xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx xxxxxxx 671) |
XX |
xxxx relevantní |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
1002 |
alkyl(C12-C18)benzyl(dimethyl)amonium-chloridy(jiné xxx látka spadající xxx xxxxxxx 667) |
IT |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- chloridy (xxxx xxx xxxxx xxxxxxxxx pod xxxxxxx 725) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1006 |
xxxxxxxxxxxxxx xxxx obsahující stříbro, xxxxx, xxxxxx x xxx |
XX |
xxxx relevantní |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx xxxxx spadající xxx xxxxxxx 673) |
IT |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od mastných xxxxxxx kokosového oleje) (xxxx než látka xxxxxxxxx xxx položku 635) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1012 |
hlinitokřemičitan xxxxx, stříbrný a xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx zeolit |
XX |
není xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (imazalil technický) |
DE |
xxxxxxxxx xx ochranu rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
Xxxx přípravků |
Xxxxx xxx xxxxxxxxxx xxxxxxxxx zprávy xxxxx čl. 6 xxxx. 3 xxxx. x) |
Xxxxx pro zahájení xxxxxxxx xxxxxxxxxx podle xx. 7 xxxx. 2 písm. b) |
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
1 x 2 |
31.12.2018 |
31.3.2019 |
6 x 13 |
31.12.2019 |
31.3.2020 |
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |